{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:28Z","timestamp":1792601608793,"version":"4.5.0"},"reference-count":183,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T00:00:00Z","timestamp":1566000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular (CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of antidiabetic medication that inhibit the absorption of glucose from the proximal tubule of the kidney and hence cause glycosuria. Four SGLT2i are currently commercially available in many countries: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT2i reduce glycated hemoglobin by 0.5%\u20131.0% and have shown favorable effects on body weight, blood pressure, lipid profile, arterial stiffness and endothelial function. More importantly, SGLT2i have demonstrated impressive cardioprotective and renoprotective effects. The main mechanisms underlying their cardioprotective effects have been attributed to improvement in cardiac cell metabolism, improvement in ventricular loading conditions, inhibition of the Na+\/H+ exchange in the myocardial cells, alteration in adipokines and cytokines production, as well as reduction of cardiac cells necrosis and cardiac fibrosis. The main adverse events of SGLT2i include urinary tract and genital infections, as well as euglycemic diabetic ketoacidosis. Concerns have also been raised about the association of SGLT2i with lower limb amputations, Fournier gangrene, risk of bone fractures, female breast cancer, male bladder cancer, orthostatic hypotension, and acute kidney injury.<\/jats:p>","DOI":"10.3390\/ijerph16162965","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T06:10:14Z","timestamp":1566195014000},"page":"2965","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":243,"title":["SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects"],"prefix":"10.3390","volume":"16","author":[{"given":"Anastasios","family":"Tentolouris","sequence":"first","affiliation":[{"name":"Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-4942","authenticated-orcid":false,"given":"Panayotis","family":"Vlachakis","sequence":"additional","affiliation":[{"name":"Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Tzeravini","sequence":"additional","affiliation":[{"name":"Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Eleftheriadou","sequence":"additional","affiliation":[{"name":"Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tentolouris","sequence":"additional","affiliation":[{"name":"Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,17]]},"reference":[{"key":"ref_1","unstructured":"International Diabetes Federation (2017). IDF Diabetes Atlas, International Diabetes Federation. [8th ed.]. Available online: http:\/\/www.diabetesatlas.org."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"ref_3","unstructured":"Tentolouris, A., Eleftheriadou, I., Athanasakis, K., Kyriopoulos, J., Tsilimigras, D.I., Grigoropoulou, P., Doupis, J., and Tentolouris, N. (2018). Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with the general population. Hellenic J. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2174\/0929867324666170530075533","article-title":"Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications","volume":"25","author":"Eleftheriadou","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2019). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care, 42, S90\u2013S102.","DOI":"10.2337\/dc19-S009"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00592-018-1206-z","article-title":"The roots of SGLT inhibition: Laurent-Guillaume de Koninck, Jean Servais Stas and Freiherr Josef von Mering","volume":"56","author":"Jorgens","year":"2019","journal-title":"Acta Diabetol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1042\/bj0251128","article-title":"The relation of glycosuria to glycaemia and the determination of the renal threshold for glucose","volume":"25","author":"Himsworth","year":"1931","journal-title":"Biochem. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/dc18-0588","article-title":"SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management","volume":"41","author":"Muskiet","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI102424","article-title":"Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose","volume":"30","author":"Farber","year":"1951","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.ajkd.2018.03.022","article-title":"SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review","volume":"72","author":"Alicic","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Choi, C.I. (2016). Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents. Molecules, 21.","DOI":"10.3390\/molecules21091136"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2","volume":"61","author":"Ghezzi","year":"2018","journal-title":"Diabetologia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1021\/jm100332n","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"53","author":"Nomura","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1021\/jm200049r","article-title":"Discovery of a clinical candidate from the structurally unique dioxa-bicyclo [3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors","volume":"54","author":"Mascitti","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-naive patients with diabetes: A randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bailey, C.J., Gross, J.L., Hennicken, D., Iqbal, N., Mansfield, T.A., and List, J.F. (2013). Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial. BMC Med., 11.","DOI":"10.1186\/1741-7015-11-43"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/dom.12239","article-title":"Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: A systematic review and network meta-analysis","volume":"16","author":"Goring","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s13300-014-0072-0","article-title":"Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: A randomized, double-blind, parallel-group, placebo-controlled trial","volume":"5","author":"Strojek","year":"2014","journal-title":"Diabetes Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"37","author":"Jabbour","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e004619","DOI":"10.1136\/bmjopen-2013-004619","article-title":"The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomised controlled trials","volume":"4","author":"Sun","year":"2014","journal-title":"BMJ Open"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Clar, C., Gill, J.A., Court, R., and Waugh, N. (2012). Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open, 2.","DOI":"10.1136\/bmjopen-2012-001007"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2013.850066","article-title":"Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study","volume":"30","author":"Stenlof","year":"2014","journal-title":"Curr. Med. Res Opin."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00228-015-1923-y","article-title":"Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: A meta-analysis","volume":"71","author":"Yang","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.12684","article-title":"Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12933-016-0407-4","article-title":"Efficacy and safety of canagliflozin in combination with insulin: A double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus","volume":"15","author":"Inagaki","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc15-1736","article-title":"Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/dc13-2762","article-title":"Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00228-014-1730-x","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes: Systematic review and meta-analysis","volume":"70","author":"Yang","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4158\/EP-2017-0066","article-title":"Hba1c Control and Cost-Effectiveness in Patients with Type 2 Diabetes Mellitus Initiated on Canagliflozin or a Glucagon-Like Peptide 1 Receptor Agonist in a Real-World Setting","volume":"24","author":"Wysham","year":"2018","journal-title":"Endocr. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"Haring","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Haring","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: A 24-week randomized, double-blind, parallel-group trial","volume":"40","author":"Softeland","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Terauchi, Y., Utsunomiya, K., Yasui, A., Seki, T., Cheng, G., Shiki, K., and Lee, J. (2019). Safety and efficacy of empagliflozin as add-on therapy to glp-1 receptor agonist (liraglutide) in japanese patients with type 2 diabetes mellitus: A randomised, double-blind, parallel-group phase 4 study. Diabetes Ther.","DOI":"10.1007\/s13300-019-0604-8"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstrale","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12888","article-title":"Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone","volume":"19","author":"Terra","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/dom.13251","article-title":"Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study","volume":"20","author":"Aronson","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13300-017-0358-0","article-title":"Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study","volume":"9","author":"Miller","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13300-017-0354-4","article-title":"Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study","volume":"9","author":"Hollander","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Hollander, P., Hill, J., Johnson, J., Wei Jiang, Z., Golm, G., Huyck, S., Terra, S.G., Mancuso, J.P., Engel, S.S., and Lauring, B. (2019). Results of VERTIS SU extension study: Safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr. Med. Res. Opin.","DOI":"10.1080\/03007995.2019.1583450"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_66","unstructured":"(1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383\u20131389."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Silverman, M.G., Zelniker, T.A., Kuder, J.F., and Murphy, S.A. (2018). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1812389"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ahj.2018.08.016","article-title":"Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)","volume":"206","author":"Cannon","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Toyama, T., Neuen, B.L., Jun, M., Ohkuma, T., Neal, B., Jardine, M.J., Heerspink, H.L., Wong, M.G., Ninomiya, T., and Wada, T. (2019). Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes. Metab.","DOI":"10.1111\/dom.13648"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): A multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1161\/CIRCRESAHA.115.306883","article-title":"Obesity and Cardiovascular Disease","volume":"118","author":"Ortega","year":"2016","journal-title":"Circ. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.12578","article-title":"Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition","volume":"18","author":"Rajeev","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Mearns, E.S., Sobieraj, D.M., White, C.M., Saulsberry, W.J., Kohn, C.G., Doleh, Y., Zaccaro, E., and Coleman, C.I. (2015). Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: A network meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125879"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Mazidi, M., Rezaie, P., Gao, H.K., and Kengne, A.P. (2017). Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients. J. Am. Heart Assoc., 6.","DOI":"10.1161\/JAHA.116.004007"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Baker, W.L., Buckley, L.F., Kelly, M.S., Bucheit, J.D., Parod, E.D., Brown, R., Carbone, S., Abbate, A., and Dixon, D.L. (2017). Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. J. Am. Heart Assoc., 6.","DOI":"10.1161\/JAHA.117.005686"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Coordinators for the, A.C.R.G.T.A.; Lipid-Lowering Treatment to Prevent Heart Attack, T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"Officers","year":"2002","journal-title":"JAMA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., Edwards, R., Agarwal, R., Bakris, G., and Bull, S. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1811744"},{"key":"ref_86","unstructured":"(2019, June 01). Clinicaltrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03036150."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1479164118783756","article-title":"Effects of sodium glucose co-transporter 2 inhibitors on the kidney","volume":"15","author":"Neeland","year":"2018","journal-title":"Diab. Vasc. Dis. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: Where are we?","volume":"58","author":"Verges","year":"2015","journal-title":"Diabetologia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and meta-analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Storgaard, H., Gluud, L.L., Bennett, C., Grondahl, M.F., Christensen, M.B., Knop, F.K., and Vilsboll, T. (2016). Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166125"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Zhang, X.L., Zhu, Q.Q., Chen, Y.H., Li, X.L., Chen, F., Huang, J.A., and Xu, B. (2018). Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. J. Am. Heart Assoc., 7.","DOI":"10.1161\/JAHA.117.007165"},{"key":"ref_94","first-page":"1113","article-title":"SGLT-2 inhibitors: Pharmacokinetics characteristics and effects on lipids","volume":"14","author":"Tsimihodimos","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2009.10.061","article-title":"Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis","volume":"55","author":"Vlachopoulos","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1232583","DOI":"10.1155\/2018\/1232583","article-title":"Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis","volume":"2018","author":"Batzias","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2169\/internalmedicine.0701-17","article-title":"The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus","volume":"57","author":"Sugiyama","year":"2018","journal-title":"Intern. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-017-0532-8","article-title":"Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: The EMBLEM trial","volume":"16","author":"Tanaka","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Tentolouris, A., Eleftheriadou, I., Tzeravini, E., Tsilingiris, D., Paschou, S.A., Siasos, G., and Tentolouris, N. (2019). Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. Curr. Med. Chem., Epub ahead of print.","DOI":"10.2174\/0929867326666190119154152"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","article-title":"Direct cardiovascular impact of SGLT2 inhibitors: Mechanisms and effects","volume":"23","author":"Kaplan","year":"2018","journal-title":"Heart Fail. Rev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17425255.2019.1588886","article-title":"Metabolism of the failing heart and the impact of SGLT2 inhibitors","volume":"15","author":"Zafar","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2147\/VHRM.S11681","article-title":"Diabetic cardiomyopathy: From the pathophysiology of the cardiac myocytes to current diagnosis and management strategies","volume":"6","author":"Voulgari","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Qiu, H., Novikov, A., and Vallon, V. (2017). Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab. Res. Rev., 33.","DOI":"10.1002\/dmrr.2886"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.diabet.2018.06.005","article-title":"SGLT2 inhibition and glucagon secretion in humans","volume":"44","author":"Saponaro","year":"2018","journal-title":"Diabetes Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV Protection in the EMPA-REG OUTCOME Trial: A \u201cThrifty Substrate\u201d Hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.metabol.2017.08.005","article-title":"The diabetic heart utilizes ketone bodies as an energy source","volume":"77","author":"Mizuno","year":"2017","journal-title":"Metabolism"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"50A","DOI":"10.1016\/S0002-9149(97)00458-X","article-title":"Substrate signaling by insulin: A ketone bodies ratio mimics insulin action in heart","volume":"80","author":"Kashiwaya","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"H1060","DOI":"10.1152\/ajpheart.00646.2012","article-title":"Ketone body metabolism and cardiovascular disease","volume":"304","author":"Cotter","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","article-title":"Empagliflozin\u2019s Fuel Hypothesis: Not so Soon","volume":"24","author":"Lopaschuk","year":"2016","journal-title":"Cell Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","article-title":"Effect of Empagliflozin on the Metabolic Signature of Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease","volume":"136","author":"Kappel","year":"2017","journal-title":"Circulation"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s00125-019-4819-z","article-title":"Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1","volume":"62","author":"Mustroph","year":"2019","journal-title":"Diabetologia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure","volume":"2","author":"Verma","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 Inhibition and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00125-005-0091-5","article-title":"Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db\/db mice","volume":"49","author":"Anzawa","year":"2006","journal-title":"Diabetologia"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab. Vasc. Dis. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1097\/01.ASN.0000083903.18724.93","article-title":"Acidosis downregulates leptin production from cultured adipocytes through a glucose transport-dependent post-transcriptional mechanism","volume":"14","author":"Teta","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.carpath.2005.01.005","article-title":"Cardiac remodeling and failure from molecules to man (Part II)","volume":"14","author":"Fedak","year":"2005","journal-title":"Cardiovasc. Pathol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.cjca.2017.07.330","article-title":"Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: Novel translational clues to EMPA-REG Outcome","volume":"33","author":"Kang","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"ref_131","unstructured":"(2019, June 01). U.S. Food and Drug Administration: Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood, Available online: https:\/\/www.fda.gov\/media\/92185\/download."},{"key":"ref_132","unstructured":"(2019, June 01). European Medicines Agency: Review of diabetes medicines called SGLT2 inhibitors started: Risk of diabetic ketoacidosis to be examined. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/sglt2inhibitorsarticle20procedurereviewstarted_en.pdf."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dom.13012","article-title":"Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature","volume":"20","author":"Bonora","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","article-title":"Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials","volume":"130","author":"Monami","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diabres.2017.04.004","article-title":"Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents","volume":"128","author":"Wang","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA Adverse Event Reporting System","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Blau, J.E., Tella, S.H., Taylor, S.I., and Rother, K.I. (2017). Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab. Res. Rev., 33.","DOI":"10.1002\/dmrr.2924"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.diabres.2017.06.018","article-title":"Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program","volume":"130","author":"Gadzhanova","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"ref_146","first-page":"1098","article-title":"Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. Nutrition, metabolism, and cardiovascular diseases","volume":"27","author":"Raschi","year":"2017","journal-title":"NMCD"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bcp.13782","article-title":"Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: A prescription sequence symmetry analysis","volume":"85","author":"Adimadhyam","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcd.2017.06.004","article-title":"Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit","volume":"12","author":"Thong","year":"2018","journal-title":"Prim. Care Diabetes"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/00325481.2016.1167570","article-title":"Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes","volume":"128","author":"Arakaki","year":"2016","journal-title":"Postgrad. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1185\/03007995.2014.890925","article-title":"Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: A pooled analysis of clinical studies","volume":"30","author":"Nyirjesy","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_151","unstructured":"(2019, June 01). U.S. Food and Drug Administration, Available online: Available online: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm617360.htm."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bone.2015.04.026","article-title":"Effects of diabetes drugs on the skeleton","volume":"82","author":"Meier","year":"2016","journal-title":"Bone"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/00325481.2017.1256747","article-title":"Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus","volume":"129","author":"Blevins","year":"2017","journal-title":"Postgrad. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: A network and cumulative meta-analysis of randomized controlled trials","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Ruanpeng, D., Ungprasert, P., Sangtian, J., and Harindhanavudhi, T. (2017). Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes Metab. Res. Rev., 33.","DOI":"10.1002\/dmrr.2903"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.diabres.2018.10.019","article-title":"Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials","volume":"146","author":"Azharuddin","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Fralick, M., Kim, S.C., Schneeweiss, S., Kim, D., Redelmeier, D.A., and Patorno, E. (2019). Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. Ann. Intern. Med.","DOI":"10.7326\/M18-0567"},{"key":"ref_159","unstructured":"(2019, June 01). U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM558427.pdf."},{"key":"ref_160","unstructured":"(2019, June 01). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/sglt2-inhibitors-previously-canagliflozin."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.diabet.2018.02.001","article-title":"Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials","volume":"44","author":"Li","year":"2018","journal-title":"Diabetes Metab."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb\/III clinical trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Katsiki, N., Dimitriadis, G., Hahalis, G., Papanas, N., Tentolouris, N., Triposkiadis, F., Tsimihodimos, V., Tsioufis, C., Mikhailidis, D.P., and Mantzoros, C. (2019). Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: An expert panel overview of the evidence. Metabolism.","DOI":"10.1016\/j.metabol.2019.04.008"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13477","article-title":"Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"21","author":"Dawwas","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/dom.13459","article-title":"Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study","volume":"20","author":"Adimadhyam","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/dom.13115","article-title":"Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study","volume":"20","author":"Yuan","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","article-title":"Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14656566.2017.1408792","article-title":"Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: Interim results of the STELLA-LONG TERM post-marketing surveillance study","volume":"19","author":"Nakamura","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.13213","article-title":"Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP\/INS)","volume":"20","author":"Terauchi","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/14656566.2019.1598378","article-title":"Advancing pharmacotherapy for diabetic foot ulcers","volume":"20","author":"Eleftheriadou","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"719578","DOI":"10.1155\/2014\/719578","article-title":"A Review on the Relationship between SGLT2 Inhibitors and Cancer","volume":"2014","author":"Lin","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.phrs.2016.07.001","article-title":"Pharmacological aspects of the safety of gliflozins","volume":"118","author":"Faillie","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11892-016-0789-4","article-title":"SGLT2 Inhibitors: Benefit\/Risk Balance","volume":"16","author":"Scheen","year":"2016","journal-title":"Curr. Diabetes Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J. Am. Soc. Hypertens. JASH"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","article-title":"An update on the safety of SGLT2 inhibitors","volume":"18","author":"Scheen","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_180","unstructured":"(2019, June 01). U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin-invokana-invokamet-and."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","article-title":"Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia","volume":"41","author":"Szalat","year":"2018","journal-title":"Drug Saf."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/dom.12917","article-title":"Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials","volume":"19","author":"Tang","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/16\/2965\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:11:54Z","timestamp":1760188314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/16\/2965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,17]]},"references-count":183,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["ijerph16162965"],"URL":"https:\/\/doi.org\/10.3390\/ijerph16162965","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,17]]}}}